The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankruptcy in the coming weeks. The San Francisco-based medical genetics ...

Mutations to the BRCA1 and BRCA2 genes significantly increase the chances of breast and ovarian cancers, and a test can assess a person’s risk from those variants. But those genes are just two of the ...

Ciitizen is a patient-centric consumer health tech platform that helps patients collect, organize, store and share their medical records digitally. With the divestiture, the Ciitizen assets have been ...

NEW YORK (Reuters) - Invitae Corp received court approval on Thursday to run a five-month bankruptcy sale process, allowing the genetic testing company to find a buyer and exit from Chapter 11 by late ...

As the biotech industry's premiere manufacturer of genetic sequencing hardware and molecular biology reagent kits, Illumina powers drug development and clinical genomics alike. Between acquiring the ...

This week, Invitae put out a press release highlighting the insights Praxis Precision Medicines was getting from Invitae's Citizen platform. The platform enables companies to get medical history data ...

Invitae (NYSE: NVTA) has grown revenue over time, but the genetic testing specialist has failed to turn that into profit. Instead, the company burned through more and more cash, prompting it to launch ...

Invitae is boosting its neurology and cardiology diagnostic test offerings. The San Francisco-based company will be adding 11 panels for heritable diseases and will update 17 existing neurology panels ...

Invitae’s (NVTA) significant revenue growth in its most recently reported quarter and its success in bringing customized health monitoring into the mainstream have heightened investor optimism around ...

Invitae (NYSE: NVTA) shares have plummeted more than 80% this year. The genetic testing company has grown revenue over the years, but it hasn't been able to turn that revenue into profit. Instead, ...